LNAI

Lunai Bioworks Inc.

Lunai Bioworks Inc. (LNAI) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $829.7K
TTM Revenue $52.0K
Price / Sales 16.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) C+ (2.5) C- (2.0) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-06 B- (2.9) C+ (2.5) C- (2.1) C+ (2.5) C+ (2.7) C+ (2.5)
2026-10-30 B- (2.9) C+ (2.5) C- (2.0) F (0.6) C+ (2.7) C- (2.1)
2026-10-23 C+ (2.8) C+ (2.5) C- (2.0) D- (1.0) C+ (2.6) C (2.2)
2026-10-16 C+ (2.6) C+ (2.5) C- (2.0) D- (1.1) C+ (2.6) C (2.2)
Page 1 of 4